Avacincaptad Pegol is named as a drug or biological intervention in 2 clinical trials in our USA, Ireland and UK trial registers, 1 of which is recruiting. Lead sponsors include ONL Therapeutics (1) and Astellas Pharma Global Development, Inc. (1). Registered phases: Phase 2 and Observational. Conditions studied include Geographic Atrophy (GA); Age - Related Macular Degeneration (AMD); Geographic Atrophy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06659445 | Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD) |
Phase 2 | Recruiting |
| NCT06779773 | A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy (ClinicalTrials.gov ↗) Geographic Atrophy, Macular Degeneration |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Geographic Atrophy (GA) | 1 |
| Age - Related Macular Degeneration (AMD) | 1 |
| Geographic Atrophy | 1 |
| Macular Degeneration | 1 |
| Lead sponsor | Trials |
|---|---|
| ONL Therapeutics | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Register | Avacincaptad Pegol trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in Ireland | 1 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Avacincaptad Pegol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avacincaptad Pegol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.